Results 141 to 150 of about 29,074 (242)

Research progress on the molecular mechanisms of PD-1 and LAG-3 synergy in regulating T cell exhaustion and immunotherapy. [PDF]

Ann Med
Li M, Duan D, Liu C, Xiong Q.
europepmc   +1 more source

To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies. [PDF]

Front Immunol
Paulsen JS, Slørdahl TS.
europepmc   +1 more source

China’s bispecific bet [PDF]

Nature Biotechnology, 2019
openaire   +1 more source

Steady‐state mobilization with on‐demand plerixafor after CD38 antibody‐based induction in multiple myeloma patients

Transfusion, EarlyView.
Abstract Background High‐dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for fit patients with newly diagnosed multiple myeloma (MM). The increasing use of CD38 antibody‐based quadruplet induction regimens such as daratumumab‐VTd (Dara‐VTd) has raised concerns regarding impaired stem cell ...
Maximilian Alexander Röhnert, Anna Seifert, Karolin Trautmann‐Grill, Christoph Röllig, Kristin Zimmer, Katharina Egger‐Heidrich, Marius Bill, Lisa Heberling, Freya Schulze, Matthias Blechschmidt, Malte von Bonin, Martin Bornhäuser, Kristina Hölig, Raphael Teipel   +13 more
wiley   +1 more source

CAR-T and BiTE: new horizons in the treatment of rheumatic autoimmune diseases. [PDF]

Front Immunol
Li J, Guo Q, Li L, Wang J, Zhang L.
europepmc   +1 more source

Bispecific biologics rush [PDF]

Nature Biotechnology, 2011
openaire   +1 more source

Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021

International Journal of Cancer, Volume 158, Issue 8, Page 2179-2185, 15 April 2026.
What's New? Liver metastasis is an indicator of life expectancy for patients with advanced uveal melanoma (UM). Data on anticipated survival time following the diagnosis of liver metastasis, however, is lacking. The present study analyzed long‐term survival among UM patients who lived three or more years after liver metastases were diagnosed.
Jona Laukhuf, Lisa Wiens, Gerd Grözinger, Helmut Dittmann, Karolin Thiel, Ulrike Leiter, Teresa Amaral, Lena Nanz, Lukas Flatz, Markus Reitmajer, Andrea Forschner   +10 more
wiley   +1 more source

Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: the Vanderbilt experience. [PDF]

Front Immunol
Marneni N, Lessans S, Dholaria B, Sengsayadeth S, Biltibo EA, Patel V, Bhaskar S, Jayani R, Mohan S, Kishtagari A, Morgan D, Oluwole OO, Savani BN, Kassim AA, Baljevic M.   +14 more
europepmc   +1 more source

Clinical Characteristics and Prognostic Risk Factors for Pediatric B‐Cell Lymphoblastic Lymphoma: A Multicenter Retrospective Cohort Study for China Net Childhood Lymphoma

Pediatric Blood &Cancer, Volume 73, Issue 4, April 2026.
ABSTRACT Background B‐cell lymphoblastic lymphoma (B‐LBL) represents a rare variety of non‐Hodgkin lymphoma, with limited research on its biology, progression, and management. Methods A retrospective analysis was performed on the clinical characteristics of 256 patients aged ≤18 years who received treatment under the China Net Childhood Lymphoma (CNCL)‐
Zhijuan Liu, Jian Wang, Ling Jin, Yanlong Duan, Fu Li, Yueping Jia, Leping Zhang, Xiaojun Yuan, Wei Liu, Ying Liu, Ansheng Liu, Mincui Zheng, Yunpeng Dai, Lian Jiang, Lirong Sun, Xiaowen Zhai, Rong Liu, Chunju Zhou, Zifen Gao, Yonghong Zhang, Xiaomei Yang   +20 more
wiley   +1 more source

A Generalized Minimal PBPK-PD Model of Bispecific Antibodies: Case Studies and Applications in Drug Development. [PDF]

CPT Pharmacometrics Syst Pharmacol
Spinosa P, Joslyn L, Ramanujan S, Gadkar K, Hosseini I.   +4 more
europepmc   +1 more source